Lisata Therapeutics (LSTA) Q4 2024 earnings summary

Executive summary

• Advanced development of certepetide for solid tumors, with promising early clinical and preclinical data, including improved survival in mPDAC and positive trends in ASCEND and iLSTA trials.

• Expanded certepetide's investigation into non-oncology indications such as endometriosis and established new preclinical collaborations.

• Seasoned management team with global drug development experience and proprietary technology protected by global IP extending beyond 2040.

• Achieved all 2024 milestones, with multiple key clinical readouts and business milestones anticipated in 2025 and into 2026.

• Cash runway extends into Q2 2026 with no debt, funding all current clinical programs.

Financial highlights

• 2024 revenue was $1 million, attributed to an upfront license fee from a collaboration; no revenue was reported in 2023.

• Operating expenses decreased to $23.4 million in 2024 from $25.7 million in 2023, an 8.9% reduction.

• Research and development expenses fell to $11.3 million (down 11%), and general and administrative expenses dropped to $12.1 million (down 6.9%) year-over-year.

• Net loss was $20 million in 2024, slightly improved from $20.8 million in 2023.

• Cash, cash equivalents, and marketable securities totaled $31.2 million at year-end 2024, with no debt.

• Received $0.9 million in non-dilutive funding from the New Jersey Economic Development Authority's tax certificate program.

Outlook and guidance

• Multiple key clinical data readouts expected in 2025, including from ASCEND Cohort B, BOLSTER, CendFox, Qilu, and iLSTA trials.

• Anticipates a data-rich year with several milestones and potential phase 3 trial planning for certepetide in pancreatic cancer.

• Focused on initiating only those trials that can be funded with existing or guaranteed capital.